Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.

Home | go to homepage
SCIENCE
  • SCIENCE
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Cardiovascular
    • Atherothrombosis
    • Dyslipidemia
    • Thrombosis
  • Diabetes
  • Eosinophilic Esophagitis
  • Multiple Sclerosis
  • Nasal Polyps
  • Prurigo Nodularis
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Meningitis
    • Pertussis & Polio
    • RSV
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Atopic Dermatitis
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
      • Clinical and economic value of SOLIQUA - Pharmacist perspective
  • Nasal Polyps
  • Rare Diseases
PRODUCTS
  • PRODUCTS
  • Amaryl®
  • Apidra®
  • Aprovel®
  • Aubagio®
  • Cerezyme
  • Clexane®
  • Depakine®
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Lantus®
  • Lemtrada®
  • Plavix®
  • Praluent®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
    • Soli-Simplify Study
  • Tavanic®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
    • Real world Evidences
  • LOGIN
  • SIGN UP
  • SEARCH
    Home | go to homepage
  • LOGIN
  • SIGN UP
  • SEARCH
    Home | go to homepage
    SCIENCE
    • SCIENCE
    • Asthma
    • Atopic Dermatitis
    • Cardiovascular
      • Cardiovascular
      • Atherothrombosis
      • Dyslipidemia
      • Thrombosis
    • Diabetes
    • Eosinophilic Esophagitis
    • Multiple Sclerosis
    • Nasal Polyps
    • Prurigo Nodularis
    • Rare Diseases
    • Vaccines
      • Vaccines
      • Influenza
      • Meningitis
      • Pertussis & Polio
      • RSV
    PATIENT SUPPORT
    • PATIENT SUPPORT
    • Atopic Dermatitis
    • Diabetes
      • Diabetes
      • Tools And Resources
        • Tools And Resources
        • Toujeo Welcome Pack
        • Soliqua Welcome Pack
        • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
        • Clinical and economic value of SOLIQUA - Pharmacist perspective
    • Nasal Polyps
    • Rare Diseases
    PRODUCTS
    • PRODUCTS
    • Amaryl®
    • Apidra®
    • Aprovel®
    • Aubagio®
    • Cerezyme
    • Clexane®
    • Depakine®
    • Dupixent®
      • Dupixent®
      • Atopic Dermatitis
      • Asthma
      • Nasal Polyps
    • Lantus®
    • Lemtrada®
    • Plavix®
    • Praluent®
    • Soliqua®
      • Soliqua®
      • Soliqua®
      • SoliMix Study
      • For a Peaceful Ramadan
      • Soli-Simplify Study
    • Tavanic®
    • Toujeo®
      • Toujeo®
      • Toujeo®
      • For a Peaceful Ramadan
      • Time-in-Range
      • Real world Evidences
  • LOGIN
  • SIGN UP
  • SEARCH
    • Home
    • Science
    • Cardiovascular
    • Atherothrombosis

    Atherothrombosis

    Discover more on science updates, events, KOLs interviews and more on Atherothrombosis

    Science in Atherothrombosis

    Get a 360º view and stay up-to-date on Atherothrombosis with content selected for you

    In hospital outcomes in young patients with AMI: Results from Gulf Coast

    Adherence and persistence analysis in patients treated with DAPT

    Test Blurred Text Login Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice

    Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)

    Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice

    Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?

    SEE EVERYTHING

    Inspiration and innovation

    Get inspired and stay at the forefront of innovation with the following resources

    Understanding de-escalation in antiplatelet therapy

    Single antiplatelet therapy Insights on earlier use

    Effectiveness and Safety of Clopidogrel vs Aspirin

    DAPT in Elderly with CAD Meta Analysis

    Management of antithrombotic therapy in patients with AF undergoing PCI

    Clopidogrel as the standard of care for elective PCI: Findings from the ALPHEUS

    SEE EVERYTHING
    Home | go to homepage

    SANOFI, Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE |

    Tel.: +971 4 550 3600 | Fax: +971 4 5521050

    For further Medical Information:

    please contact: +971 565776791 or Email: medical-information.gulf@sanofi.com

    To report an adverse event:

    please call: +971 561747001 or Email: Gulf.pharmacovigilance@sanofi.com

    To report any product technical complaints, kindly contact: Email: quality.greatergulf@sanofi.com

     

    MAT-BH-2100734/V4/Oct 2022

    • Legal notice
    • Cookie policy
    • Privacy policy
    • Sitemap
    • Change country

    YOU WILL NOW BE LEAVING THE SITE

    By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
    Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.

    Continue
    This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.
     
    Please choose if you are a healthcare professional and wish to continue on this site or if you are a member of the public to be redirected to the Sanofi website.